SS 32 - CNS 2: Gliomas: Survivorship and Clinical Trials

Presentations

• 08:00am - 09:00am PT

  CNS 2: Gliomas: Survivorship and Clinical Trials

  Speaker: Kelli Pointer, MD, PhD - Dartmouth Cancer Center, Lebanon
• 08:00am - 09:00am PT

  CNS 2: Gliomas: Survivorship and Clinical Trials

  Speaker: Steve Braunstein, MD, PhD - University of California, San Francisco, San Francisco
• 08:10am - 08:20am PT

  WF-1801: Cognitive Outcomes of a Single Arm Pilot Study of Ramipril for Prevention of Radiation-Induced Cognitive Decline in Glioblastoma Patients Receiving Chemoradiotherapy

  Speaker: Amanda Goetz, MD, MS - Atrium Health Wake Forest Baptist, Lexington
• 08:20am - 08:30am PT

  Validating the FACT-Br Cognitive Index for Early Detection of Radiation-Induced Cognitive Decline in Primary Brain Tumors

  Speaker: Ariana Chirban, BS - UC San Diego School of Medicine, La Jolla
• 08:40am - 08:50am PT

  Comparing the Effectiveness of Hypofractionated Radiotherapy with Conventional Radiotherapy in High Grade Glioma Treatment: An Open Labelled Randomized Controlled Trial in a Tertiary Care Center in Ce

  Speaker: Simran Rajian, MBBS - All India Institute of Medical Sciences, Raipur, C.G, Raipur
• 08:50am - 09:00am PT

  Discussant

  Speaker: Michelle Kim, MD - University of Michigan, Ann Arbor
• 08:30am - 08:40am PT

  Predictive Factors for Survival after Reirradiation of IDH Wild Type High Grade Glioma

  Speaker: John Petersen, DO - Wake Forest Baptist Medical Center, Winston Salem